Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• Amisulpride demonstrated significant effectiveness in preventing postoperative nausea and vomiting (PONV), with a 24-hour complete response rate (no emesis and no rescue antiemetic use) relative risk (RR) of 1.30 (95% confidence interval (CI): 1.20-1.41), particularly at a 5 mg dose (relative risk (RR): 1.28, 95% CI: 1.18-1.39).
• In treating depressive symptoms in major psychiatric disorders, amisulpride at 50 mg/day showed greater symptom reduction compared to placebo (standardized mean difference (SMD) = -0.70, 95% CI: -0.92, -0.49), and it was comparable in efficacy to selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants in the treatment of dysthymia.
• Amisulpride showed a significantly higher rate of intolerability-related discontinuations in monotherapy for major depressive disorder (MDD) compared to placebo.
• In postoperative nausea and vomiting (PONV) prevention, the adverse event profile of amisulpride was generally similar to placebo.
• The reviewed studies provide information on population types relevant to schizophrenia treatment (patients with sleep-related adverse effects), antidepressant-induced apathy (patients receiving SSRIs), major depressive disorder (adults receiving monotherapy or adjunctive antipsychotic therapy), and postoperative nausea and vomiting (adults undergoing surgery with general anesthesia).